Skip to content

Neuphoria Therapeutics Inc.: 10-Q filed 2026-05-15

What Neuphoria Therapeutics Inc. reported in its quarterly report filed 2026-05-15 (fiscal Q3 2026): 38 published measures, 112 facts as tagged in accession 0001193125-26-225442.

This filing

Form
10-Q (quarterly report)
Filed
2026-05-15
Fiscal period
fiscal Q3 2026
Accession
0001193125-26-225442 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Neuphoria Therapeutics Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-03-3134,809,200USD
At 2025-06-3028,589,614USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-03-315,385,256USD
At 2025-06-309,587,040USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-03-3129,423,944USD
At 2025-12-3129,700,824USD
At 2025-09-3012,510,187USD
At 2025-06-3019,002,574USD
At 2025-03-3125,997,308USD
At 2024-12-3113,747,995USD
At 2024-09-3017,070,364USD
At 2024-06-3017,490,372USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-03-3119,440,655USD
At 2025-06-3014,210,745USD
At 2025-03-3117,044,750USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-505,063USD90
2025-07-01 to 2026-03-31-8,547,475USD274
2025-10-01 to 2025-12-311,864,092USD92
2025-07-01 to 2025-09-30-9,906,504USD92
2025-01-01 to 2025-03-3111,262,161USD90
2024-07-01 to 2025-03-318,514,025USD274
2024-10-01 to 2024-12-31-1,943,349USD92
2024-07-01 to 2024-09-30-804,787USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-07-01 to 2026-03-31-13,566,928USD274
2024-07-01 to 2025-03-313,662,302USD274

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-01-01 to 2025-03-3115,000,000USD90
2024-07-01 to 2025-03-3115,662,715USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-07-01 to 2026-03-3117,915,883USD274
2024-07-01 to 2025-03-31823,601USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-03-31-186,894,178USD
At 2025-06-30-178,346,703USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-01-01 to 2026-03-315,411,244shares90
2025-07-01 to 2026-03-314,058,522shares274
2025-01-01 to 2025-03-311,719,073shares90
2024-07-01 to 2025-03-311,530,091shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-01-01 to 2026-03-315,411,244shares90
2025-07-01 to 2026-03-314,058,522shares274
2025-01-01 to 2025-03-311,719,073shares90
2024-07-01 to 2025-03-311,530,091shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-0.09USD/shares90
2025-07-01 to 2026-03-31-2.11USD/shares274
2025-01-01 to 2025-03-316.55USD/shares90
2024-07-01 to 2025-03-315.56USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-0.09USD/shares90
2025-07-01 to 2026-03-31-2.11USD/shares274
2025-01-01 to 2025-03-316.55USD/shares90
2024-07-01 to 2025-03-315.56USD/shares274

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-34,793USD90
2025-07-01 to 2026-03-31-104,380USD274
2025-01-01 to 2025-03-31-81,186USD90
2024-07-01 to 2025-03-31-201,764USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-06-302,771USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-07-01 to 2026-03-31275,264USD274
2024-07-01 to 2025-03-3165,505USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-1,211,649USD90
2025-07-01 to 2026-03-31-10,925,151USD274
2025-01-01 to 2025-03-3111,977,193USD90
2024-07-01 to 2025-03-314,705,955USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-03-3121,657,908USD
At 2025-06-3015,040,831USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-03-311,513,309USD
At 2025-06-304,220,760USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-03-31627,185USD
At 2025-06-301,154,369USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2026-03-318,843,549USD
At 2025-06-308,638,609USD
At 2025-03-318,451,038USD
At 2024-06-308,690,018USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2026-03-311,605,340USD
At 2025-06-3011,948USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,211,649USD90
2025-07-01 to 2026-03-3110,925,151USD274
2025-01-01 to 2025-03-313,022,807USD90
2024-07-01 to 2025-03-3110,956,760USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-03-315,377,329shares
At 2025-06-301,978,460shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-03-3119,440,655USD
At 2025-06-3014,288,690USD
At 2025-03-3117,119,482USD
At 2024-06-3012,686,935USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-03-31218,385,436USD
At 2025-06-30200,194,324USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-03-31-2,067,368USD
At 2025-06-30-2,845,066USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-06-30102,612USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2026-03-310USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2026-03-314,307,743USD
At 2025-06-304,804,791USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2026-03-31390,733USD
At 2025-06-30495,113USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-539,856USD90
2025-07-01 to 2026-03-31-8,651,855USD274
2025-01-01 to 2025-03-3111,180,975USD90
2024-07-01 to 2025-03-318,312,261USD274

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-347,166USD90
2025-07-01 to 2026-03-31-7,769,777USD274
2025-01-01 to 2025-03-3111,066,343USD90
2024-07-01 to 2025-03-317,615,155USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,687,403USD90
2025-07-01 to 2026-03-315,681,361USD274
2025-01-01 to 2025-03-311,406,796USD90
2024-07-01 to 2025-03-315,702,807USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-01-01 to 2026-03-31671,793USD90
2025-07-01 to 2026-03-312,273,296USD274
2025-01-01 to 2025-03-31-796,218USD90
2024-07-01 to 2025-03-313,606,306USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-07-01 to 2026-03-3117,915,883USD274
2024-07-01 to 2025-03-31823,601USD274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-07-01 to 2026-03-311,593,392USD274
2024-07-01 to 2025-03-31-102,292USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-07-01 to 2026-03-31-527,184USD274
2024-07-01 to 2025-03-31-1,498,326USD274

Inspect the source

Entity
Neuphoria Therapeutics Inc. / CIK 0001191070
Captured
2026-09-20T07:45:23.997Z
SEC response SHA-256
372513ea84f86f142e1c29cb2b664e83007b50ab22e27c520e32d6f65e10eeca

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001191070.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))